The Mitsubishi Tanabe Pharma Group is committed to maintaining the highest ethical standards and placing top priority on fairness and integrity in all activities. As a part of this we have a commitment to be transparent in all our interactions with the Medical Industry. We disclose these interactions on our website in line with EFPIA Code of Practice and the relevant* local codes of practice and/or local legal requirements.
We understand transparency is an important means to strengthen public trust in the Pharmaceutical Industry. We therefore make a commitment to disclose data of our relevant interactions annually with Healthcare Professionals (HCPs) Healthcare Organisations (HCOs) and Patient Organisations (POs) throughout Europe and when engaging with Members of the Public (MoP) in the United Kingdom. When we engage in any Collaborate Working, including Joint Working projects, we publish information regarding these interactions on this site.
Annual Transfer of Value Disclosures for our interactions within the Medical Industry
*The Mitsubishi Tanabe Pharma Group has established legal entities in the United Kingdom, Germany and Switzerland and therefore disclosure is made according to local requirements for these countries.
For more information on Mitsubishi Tanabe Pharma Europe’s see Mission & Vision